Pharmanutra Future Growth
Future criteria checks 4/6
Pharmanutra is forecast to grow earnings and revenue by 18.5% and 13.2% per annum respectively. EPS is expected to grow by 18.8% per annum. Return on equity is forecast to be 29.3% in 3 years.
Key information
18.5%
Earnings growth rate
18.8%
EPS growth rate
Personal Products earnings growth | 8.0% |
Revenue growth rate | 13.2% |
Future return on equity | 29.3% |
Analyst coverage | Low |
Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings
Sep 11Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 23Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
Sep 26These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely
May 16Pharmanutra (BIT:PHN) Could Easily Take On More Debt
Jan 11Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal
Nov 02Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around
Aug 03Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
May 20Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)
Apr 19Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?
Mar 10Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?
Feb 17Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?
Feb 01Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?
Jan 18Is Pharmanutra (BIT:PHN) A Risky Investment?
Jan 04Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return
Dec 22Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?
Dec 08Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 151 | 25 | 24 | 28 | 2 |
12/31/2025 | 133 | 22 | 21 | 24 | 2 |
12/31/2024 | 117 | 19 | 17 | 20 | 2 |
9/30/2024 | 113 | 16 | 19 | 23 | N/A |
6/30/2024 | 108 | 14 | 15 | 20 | N/A |
3/31/2024 | 101 | 11 | 2 | 12 | N/A |
12/31/2023 | 101 | 13 | -1 | 12 | N/A |
9/30/2023 | 95 | 12 | -5 | 12 | N/A |
6/30/2023 | 93 | 14 | -19 | 12 | N/A |
3/31/2023 | 88 | 16 | -15 | 14 | N/A |
12/31/2022 | 83 | 15 | -9 | 17 | N/A |
9/30/2022 | 79 | 16 | -5 | 19 | N/A |
6/30/2022 | 76 | 15 | 10 | 19 | N/A |
3/31/2022 | 73 | 15 | 14 | 20 | N/A |
12/31/2021 | 68 | 14 | 15 | 20 | N/A |
9/30/2021 | 65 | 14 | 13 | 16 | N/A |
6/30/2021 | 60 | 11 | 12 | 15 | N/A |
3/31/2021 | 57 | 14 | 13 | 15 | N/A |
12/31/2020 | 57 | 14 | 10 | 12 | N/A |
9/30/2020 | 58 | 14 | 11 | 11 | N/A |
6/30/2020 | 58 | 14 | 7 | 11 | N/A |
3/31/2020 | 55 | 9 | 4 | 9 | N/A |
12/31/2019 | 54 | 8 | 7 | 12 | N/A |
9/30/2019 | 49 | 8 | 3 | 8 | N/A |
6/30/2019 | 50 | 9 | 7 | 9 | N/A |
3/31/2019 | 48 | 9 | 6 | 8 | N/A |
12/31/2018 | 47 | 9 | 6 | 6 | N/A |
9/30/2018 | 44 | 8 | 5 | 6 | N/A |
6/30/2018 | 41 | 7 | N/A | 6 | N/A |
3/31/2018 | 40 | 6 | N/A | 6 | N/A |
12/31/2017 | 38 | 6 | N/A | 6 | N/A |
9/30/2017 | 37 | 5 | N/A | N/A | N/A |
6/30/2017 | 35 | 5 | N/A | N/A | N/A |
3/31/2017 | 34 | 4 | N/A | N/A | N/A |
12/31/2016 | 33 | 4 | N/A | 6 | N/A |
12/31/2015 | 26 | 3 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHN's forecast earnings growth (18.5% per year) is above the savings rate (2.5%).
Earnings vs Market: PHN's earnings (18.5% per year) are forecast to grow faster than the Italian market (7% per year).
High Growth Earnings: PHN's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHN's revenue (13.2% per year) is forecast to grow faster than the Italian market (4% per year).
High Growth Revenue: PHN's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHN's Return on Equity is forecast to be high in 3 years time (29.3%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 14:44 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmanutra S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Andrea Randone | Intermonte SIM S.p.A. |
Giorgio Tavolini | Intermonte SIM S.p.A. |
Daniele Alibrandi | Stifel, Equities Research |